publication date: Apr. 25, 2014


In Brief
Morgan Named Director Of UAMS Myeloma Institute

GARETH MORGAN was named director of the University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy.

Morgan, currently a clinician and researcher with the Myeloma UK Research Centre at the Institute of Cancer Research in London, will begin at UAMS in July. He is a director of Myeloma UK as well as a member of the Scientific Board of the International Myeloma Foundation, scientific secretary for the UK Myeloma Forum and founding director of the European Myeloma Network.

Morgan will succeed Bart Barlogie, the institute’s founder and director since 1989, who has chosen to step down, but will remain to focus on clinical care and research.

MICHAEL GORDON was named medical director for the Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute. He will oversee the center’s phase I program.

Gordon is CEO of Pinnacle Oncology Hematology, a division of Arizona Center for Cancer Care, focusing on translational research and the care and management of cancer patients seeking phase I and phase II clinical trials. He is a clinical professor of internal medicine at the University of Arizona College of Medicine and is co-director of the Oncology Block.

His principal research interests are in development of cancer therapies with a focus on targeted and immunologic therapies as well as drugs that affect angiogenesis. His disease focuses include kidney cancer, melanoma, prostate cancer, lung cancer, gastrointestinal stromal tumors and ovarian cancer.

presented … Continue reading 40-17 In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.